Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $659,700.00 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Alexander Gold sold 15,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $43.98, for a total value of $659,700.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mineralys Therapeutics Trading Down 7.8%

Shares of MLYS stock opened at $40.85 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $47.65. The company’s 50-day moving average price is $40.17 and its 200-day moving average price is $24.04. The stock has a market cap of $3.23 billion, a price-to-earnings ratio of -13.85 and a beta of 0.40.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. As a group, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analyst Weigh In

MLYS has been the topic of several analyst reports. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 22nd. HC Wainwright raised their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America upped their price target on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $46.67.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. raised its holdings in shares of Mineralys Therapeutics by 26.7% in the 1st quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company’s stock valued at $97,619,000 after buying an additional 1,296,296 shares during the period. SR One Capital Management LP grew its position in Mineralys Therapeutics by 55.1% in the 1st quarter. SR One Capital Management LP now owns 3,127,933 shares of the company’s stock valued at $49,672,000 after acquiring an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. increased its stake in Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after purchasing an additional 692,550 shares during the period. Caligan Partners LP increased its stake in Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after purchasing an additional 755,302 shares during the period. Finally, Suvretta Capital Management LLC lifted its position in shares of Mineralys Therapeutics by 22.2% during the third quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock worth $80,850,000 after purchasing an additional 387,641 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.